	US 11,707,515 B2
	*Modified Brucella* vaccine strain for the treatment of brucellosis**
María Jesús Grilló Dolset, Aranguren (ES); Beatriz San Román Aberasturi, Aranguren (ES); Leyre Palacios Chaves, Aranguren (ES); Sara Mena Bueno, Aranguren (ES); and Ana Zabalza Baranguá, Aranguren (ES)
Assigned to CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC), Madrid (ES); and UNIVERSIDAD PÚBLICA DE NAVARRA, Pamplona (ES)
Filed by CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC), Madrid (ES); and UNIVERSIDAD PÚBLICA DE NAVARRA, Pamplona (ES)
Filed on Mar. 4, 2022, as Appl. No. 17/687,313.
Application 17/687,313 is a continuation of application No. 16/766,629, granted, now 11,298,416, previously published as PCT/EP2018/082539, filed on Nov. 26, 2018.
Claims priority of application No. 17382798 (EP), filed on Nov. 24, 2017.
Prior Publication US 2022/0273785 A1, Sep. 1, 2022
Int. Cl. A61K 39/02 (2006.01); A61P 31/04 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/098 (2013.01) [A61P 31/04 (2018.01); A61K 2039/522 (2013.01)]

12 Claims

1. A vaccine composition comprising a modified Brucella melitensis Rev1 strain, wherein the wzm gene has been inactivated, and a pharmaceutically acceptable carrier, diluent and/or adjuvant.